BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31702631)

  • 1. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: A case report.
    Shen J; Luo R; Zhang L; Li Y; Ke L; Gao Z
    Medicine (Baltimore); 2019 Nov; 98(45):e17795. PubMed ID: 31702631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of electroacupuncture at Zhongliao (BL33) and other acupoints for overactive bladder symptoms.
    Yang L; Wang Y; Mo Q; Liu Z
    Front Med; 2017 Mar; 11(1):129-136. PubMed ID: 28194560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
    Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
    Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
    Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
    Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
    Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of neuromodulation in patients with neurogenic overactive bladder.
    Lay AH; Das AK
    Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
    Msika J; Kalantan M; Larre S; Leon P
    Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
    Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
    Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
    Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
    Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.
    Poole RL; Dale M; Morgan H; Oladapo T; Brookfield R; Morris R
    Appl Health Econ Health Policy; 2022 May; 20(3):305-313. PubMed ID: 34964090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation for detrusor hyperactivity with impaired contractility.
    Hennessey DB; Hoag N; Gani J
    Neurourol Urodyn; 2017 Nov; 36(8):2117-2122. PubMed ID: 28345779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sacral neuromodulation for refractory overactive bladder].
    van Ophoven A
    Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.